Table 2.

Comparison of baseline characteristics between non-tocilizumab treated and tocilizumab-treated patients who required mechanical ventilation.

	Discharged Ventilated Patient Population (N = 59*) Data through 5/18/2020
	Non-TOCI	TOCI	P-value
	(N = 15)	(N = 44)
Outcomes
Death	9 (60.0)	6 (13.6)	0.001
Overall Vent-free days	4.33 (±3.735)	9.68 (7.13)	0.008
Demographics
Gender
Female	9 (60.0)	8 (18.2)	0.006
Male	6 (40.0)	36 (81.8)
Age	73.47 (±14.0)	63.61 (±14.83)	0.03
Race
White	5 (33.3)	16 (36.4)	0.18
Asian	2 (13.3)	0 (0.0)
Black or African American	3 (20.0)	12 (27.3)
Hispanic	4 (26.7)	12 (27.3)
Other/Unknown	1 (6.7)	4 (9.1)
Comorbidities
Hypertension	11 (73.3)	26 (59.1)	0.37
Cardiac Arrhythmias	7 (46.7)	16 (36.4)	0.55
CHF	5 (33.3)	8 (18.2)	0.28
Renal Failure	5 (33.3)	14 (31.8)	1.00
Obesity (BMI > 30)	3 (20.0)	23 (52.3)	0.04
Diabetes	8 (53.3)	21 (47.7)	0.77
Initial Lab Values
ALT	34 (13−160)	36.5 (10−3460)	0.84
AST	64 (26−291)	52.5 (16−8000)	0.63
CRP	151.05 (21.3−283.2)	125.15 (11.10−343.10)	0.78
D-DIMER	2.335 (.42−14.28)	1.48 (.38−20.00)	0.34
IL-6	67.7 (4.60−955)	28.3 (3.60−6604.50)	0.14
LDH	483 (199−1110)	500.0 (210−3325)	0.37
Lymphocytes	0.50 (.06−2.89)	.53 (.00−1.63)	0.58
Neutrophils	8.3 (2.99–16.05)	5.78 (2.91−22.72)	0.12
Troponin	0.08 (.01−36.69)	.02 (.01−25.33)	0.07
WBC	9.73 (4.27−17.98)	7.44 (4.16−26.42)	0.11
SOFA Score	6 (3−13)	5 (0−13)	0.10
Hospital days prior to tocilizumab treatment, median (range)	NA	2 (0−16)	NA
Concomitant Medications
Hydroxychloroquine	5 (33.3)	33 (75.0)	0.006
Azithromycin	7 (46.7)	37 (84.1)	0.01
Remdesivir	1 (6.7)	5 (11.4)	1.00
Dexamethasone	0 (0.0)	1 (2.3)	1.00

Data are n (%), mean (±SD), and median (range). P-values were calculated using Mann–Whitney U test, t-test, chi–square test or Fisher’s exact test, as appropriate.